Drug intelligence / Profile preview

Traumaplant

Development stage
Unknown
Lead developer
Harras Pharma Curarina
Modality
Small Molecules
Administration
Topical
01

Overview

Traumaplant is a topical herbal cream developed and manufactured by Harras Pharma. It contains a specialized extract derived from the freshly harvested flowers, stems, and leaves of *Symphytum x uplandicum Nyman* (a hybrid cultivated comfrey). A defining characteristic of this product is that the comfrey variety used is specifically cultivated to be free of toxic pyrrolizidine alkaloids (PAs), which are typically a safety concern with comfrey-based products. The cream's therapeutic activity is attributed to bioactive compounds including rosmarinic acid, allantoin, and choline. Traumaplant is indicated for the treatment of pain, inflammation, and swelling associated with blunt injuries, muscle and joint pain, sprains, bruises, and abrasions. It also promotes wound healing in minor skin injuries. The product is marketed as an over-the-counter (OTC) medicinal cream in various countries, including Germany, and is distributed in the United States by EuroPharma under the Terry Naturally brand.

Brand names
TraumaplantTerry Naturally Traumaplant
Other names
Symphytum x uplandicum extract creamComfrey cream
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)C3PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ALOX5 (Arachidonate 5-lipoxygenase)

Beyond the preview

Go deeper on Traumaplant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Traumaplant.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call